Amarin Q1 2024 Earnings Report $0.54 -0.02 (-3.76%) As of 11:17 AM Eastern Earnings HistoryForecast Amarin EPS ResultsActual EPS-$0.02Consensus EPS -$0.04Beat/MissBeat by +$0.02One Year Ago EPS-$0.04Amarin Revenue ResultsActual Revenue$56.52 millionExpected Revenue$51.34 millionBeat/MissBeat by +$5.18 millionYoY Revenue GrowthN/AAmarin Announcement DetailsQuarterQ1 2024Date5/1/2024TimeBefore Market OpensConference Call ResourcesConference CallConference Call TranscriptPress ReleaseAMRN Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Powered by Amarin Earnings HeadlinesAmarin (NASDAQ:AMRN) Raised to Hold at StockNews.comJanuary 14 at 2:39 AM | americanbankingnews.comFY2024 Earnings Forecast for Amarin Issued By Zacks ResearchJanuary 13 at 1:47 AM | americanbankingnews.comNEW A.I. giant trading up to 84% less than MSFT – set to soar in 2025?I’ve traded every major tech boom since the dawn of the personal computer. And I can tell you one thing with absolute certainty… Even President Donald Trump has been watching this stock since 2020.January 16, 2025 | The Oxford Club (Ad)Amarin (NASDAQ:AMRN) Coverage Initiated by Analysts at StockNews.comJanuary 6, 2025 | americanbankingnews.comAmarin Receives National Reimbursement for VAZKEPA® in ItalyDecember 16, 2024 | globenewswire.comAmarin Corporation plc: Amarin Appoints Peter Fishman Chief Financial OfficerDecember 14, 2024 | finanznachrichten.deSee More Amarin Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Amarin? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Amarin and other key companies, straight to your email. Email Address About AmarinAmarin (NASDAQ:AMRN), a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.View Amarin ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Why Amazon’s Next Earnings Could Trigger a Stock BreakoutS&P 500 Earnings Set to Shine: January's Critical Market TestCiena Rebounds: AI and Strong Guidance Drive Post-Earnings SurgeHistory Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead? Upcoming Earnings Schlumberger (1/17/2025)Truist Financial (1/17/2025)Interactive Brokers Group (1/21/2025)Netflix (1/21/2025)HDFC Bank (1/21/2025)Charles Schwab (1/21/2025)Prologis (1/21/2025)3M (1/21/2025)Capital One Financial (1/21/2025)ICICI Bank (1/22/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
